Weight loss reduces risky decisions and boosts mood in highly obese individuals, study finds
July 21, 2024 / Weight Loss / Obesity / Weight / Glucose Regulation
Weight loss improves mood and reduces risky decision-making in highly obese individuals, likely due to better glucose regulation and psychological factors, according to a study involving a weight management program.
New opportunity to improve diagnosis, care for people with cardiovascular-kidney-metabolic syndrome
July 17, 2024 / Cardiovascular-kidney-metabolic syndrome / American Heart Association / Novo Nordisk
The American Heart Association’s new initiative, supported by Novo Nordisk and Boehringer Ingelheim, aims to improve diagnosis, care, and treatment for cardiovascular-kidney-metabolic syndrome through a comprehensive, person-centered approach and collaboration with key healthcare organizations.
Diabetes and obesity can damage the liver to the point of failure – but few people know their risk of developing liver disease
July 22, 2024 / Metabolic Liver Disease / MASLD / Diabetes / Obesity / Livery Health
Diabetes and obesity significantly increase the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, MASH. Early diagnosis and management through lifestyle changes and medications are crucial to prevent liver failure and other complications.
Weight loss linked to improved mood and reduced risk-taking in obese individuals
July 16, 2024 / Weight Loss / Metabolism / Obesity
Massive weight loss in severely obese individuals improves glucose metabolism and mood, reducing risk-taking behavior. The study highlights the significant influence of BMI on decision-making, suggesting metabolic signals become the primary influence post-weight loss.
How PCPs should care for each stage of cardiovascular-kidney-metabolic syndrome
July 19, 2024 / Cardiovascular-kidney-metabolic syndrome / Primary Care / American Heart Association
Primary care providers (PCPs) are essential in detecting and managing cardiovascular-kidney-metabolic (CKM) syndrome at each stage, from early prevention to advanced care, as outlined by the American Heart Association’s recent advisory.
Natural Compound in Olives May Help Fight Obesity And Type 2 Diabetes
July 23, 2024 / Elenolic Acid Benefits / Diabetes / Obesity / Metabolic Hormone Relese
Elenolic acid, a compound in olives, shows potential as a treatment for obesity and type 2 diabetes by reducing blood sugar levels and promoting metabolic hormone release in mouse models, outperforming some leading medications.
Study Reveals How Obesity Gene Affects the Brain
July 16, 2024 / SH2B1 Gene / Obesity / Metabolic Diseases
The SH2B1 gene, acting in the brain’s paraventricular hypothalamus, regulates appetite and energy expenditure. Mutations in SH2B1 are linked to obesity, type 2 diabetes, and metabolic diseases. Enhancing SH2B1 activity offers potential for obesity treatment without identified side effects.
Impact of Bariatric Surgery on Macular and PVD in Individuals with Obesity without Metabolic Disease
July 22, 2024 / Bariatric Surgery / Retinal Layer / Obesity / Microvascular Health
Bariatric surgery in individuals with obesity, but no metabolic disease, significantly increases macular vessel density in the deep capillary plexus and thickens retinal layers, indicating microvascular improvements independent of metabolic conditions.
Obesity Modifies Link Between Birth Weight, Metabolic Phenotypes
July 16, 2024 / Birth Weight / Obesity / Metabolic Phenotypes / Insulin Resistance / Cariometabolic Health
Obesity exacerbates the associations between lower birth weight and adverse metabolic phenotypes in children, highlighting the need for early interventions to address obesity and cardiometabolic risks, according to a study in eBioMedicine.
Dietary pyruvate targets cytosolic phospholipase A2 to mitigate inflammation and obesity in mice
July 16, 2024 / Pyruvate / Obesity / cPLA2 Inhibition
Pyruvate targets cPLA2 to inhibit adipogenesis and reduce inflammation, effectively preventing obesity and metabolic disorders in mice. This highlights pyruvate’s potential as a safe, therapeutic option for obesity treatment.
Rona raises $35m to advance RNA drugs targeting metabolic and neurodegenerative diseases
July 22, 2024 / Rona Therapeutics / siRNA / Metabolic Diseases / Neurodegenerative Diseases
Rona Therapeutics raised $35 million to advance siRNA drugs targeting metabolic and neurodegenerative diseases, including hypercholesterolemia, hypertriglyceridemia, NASH, and CNS diseases like ALS and Alzheimer’s, leveraging multiple platforms for clinical development.
Boosting Gut Health with Inulin in Children with Obesity
July 21, 2024 / Insulin / Chilldhood Obesity / Metabolic Health
Inulin supplementation in obese children enhances gut bacterial diversity, improves metabolic outcomes, and reduces systemic inflammation. This study from Chulalongkorn University highlights inulin’s potential as a therapeutic strategy for managing childhood obesity by modulating gut microbiota.
Malfunctioning immune cells may cause type 2 diabetes in obesity: study
July 21, 2024 / Obesity / Diabetes / Insulin Resistance
A study from the University of Gothenburg suggests malfunctioning immune cells (macrophages) in adipose tissue contribute to type 2 diabetes in obesity by failing to clear collagen fragments, leading to inflammation and insulin resistance.
MASH therapies still needed despite boom in GLP-1 use in liver disease
July 16, 2024 / MASH Treatment / GLP-1 Receptor / Liver Disease
GLP-1 receptor agonists show potential for treating metabolic dysfunction-associated steatohepatitis (MASH), but more data is needed on their benefits. Combining GLP-1s with liver-specific medications like resmetirom and lifestyle interventions is crucial for effective management.
Circadian Syndrome Superior Predictor to Metabolic Syndrome of Prevalent Psoriasis
July 22, 2024 / CiracadianSyndrome / Mental Health / Psoriasis / Hypertension
Circadian syndrome (CircS) predicts psoriasis better than metabolic syndrome (MetS). Factors like depressive symptoms, high blood pressure, and increased waist circumference are significant predictors, highlighting the importance of CircS in identifying psoriasis risk.
What is the association of Mediterranean diet–based interventions with cardiometabolic biomarkers in children and adolescents?
July 16, 2024 / Mediterrranean Diet / Obesity / Blood Pressure
Mediterranean diet-based interventions in children and adolescents significantly reduce systolic blood pressure, triglycerides, total cholesterol, and LDL-C, while increasing HDL-C, highlighting their potential in improving cardiometabolic health.
Joint association of sleep quality and physical activity with metabolic dysfunction-associated fatty liver disease: a population-based cross-sectional study in Western China
July 22, 2024 / MAFLD / Sleep Quality / Liver Health
Poor sleep quality and physical inactivity independently and jointly increase the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD). Improving sleep quality significantly reduces MAFLD risk, highlighting the need for strategies targeting both sleep and physical activity.
Bitter-taste vegetables in Asian diets may help reduce metabolic syndrome risk factors in children
July 16, 2024 / Childhood Obesity / Metabolic Syndrome / Metabolic Health
Bitter-taste vegetables, particularly from the Brassicaceae family, may reduce metabolic syndrome risk factors in children by leveraging their anti-inflammatory and antioxidant properties. Increasing intake of these vegetables is crucial for preventing obesity-related metabolic disorders in Asian children.
Testosterone Increases Metabolic Syndrome Risk in Trans Men
July 17, 2024 / Testosterone / Metabolic Syndrome / Hormone Therapy / Metabolic Health
Long-term testosterone treatment in trans men increases metabolic syndrome risk, while estradiol in trans women lowers it. This highlights the need for monitoring metabolic health in transgender individuals undergoing hormone therapy.